{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T19:31:01Z","timestamp":1793475061297,"version":"4.5.0"},"reference-count":15,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Bone Miner Metab"],"published-print":{"date-parts":[[2026,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>\n                      Eldecalcitol is an active vitamin D\n                      <jats:sub>3<\/jats:sub>\n                      derivative approved for the treatment of osteoporosis in Japan and postmenopausal osteoporosis in China. However, the impact of concomitant calcium supplementation on its safety profile is unclear.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This was a prospective, observational, non-interventional post-marketing drug intensive monitoring study in Chinese postmenopausal women with osteoporosis (NCT05433207). Data were collected using an electronic case report form at baseline, before initial eldecalcitol dosing, and during routine clinical visits over a 1-year follow-up period.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      One thousand patients were enrolled from 29 Chinese clinical sites; 958 received eldecalcitol (853 without\/105 with calcium supplementation). The mean age (standard deviation [SD]) of patients was 65.6 (9.0) years and mean (SD) time since osteoporosis diagnosis was 2.7 (3.8) years. Adverse drug reactions (ADRs) affected 39.2% and 42.9% of patients in the without and with calcium supplementation groups, respectively. 22 (2.3%) patients developed hypercalcemia including 17 (1.99%) and 5 (4.76%) in the without and with calcium supplementation groups, respectively. Multivariable logistic regression analyses indicated that those receiving calcium were more likely to experience hypercalcemia (adjusted odds ratio [OR] 3.07, 95% confidence interval [CI] 1.16, 8.10,\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.02) than those not receiving calcium. ADRs of urolithiasis were experienced by three patients (0.35%) in the without calcium supplementation group.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study confirmed the real-world safety profile of eldecalcitol in a large population of Chinese women with postmenopausal osteoporosis. Hypercalcemia incidence was higher in patients with compared to without calcium supplementation, indicating that concomitant eldecalcitol and calcium should be carefully considered.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00774-026-01735-x","type":"journal-article","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:26:53Z","timestamp":1781634413000},"page":"597-609","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Eldecalcitol and calcium supplementation in Chinese women with postmenopausal osteoporosis: a prospective observational cohort study"],"prefix":"10.1007","volume":"44","author":[{"given":"Yan","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuhong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youjia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoujin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglai","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianjun","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuanxia","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qifeng","family":"Ying","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shun","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiemi","family":"Yamagiwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Ke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weibo","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhiro","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,16]]},"reference":[{"key":"1735_CR1","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1007\/s00198-021-05900-y","volume":"33","author":"MS LeBoff","year":"2022","unstructured":"LeBoff MS, Greenspan SL, Insogna KL, Lewiecki EM, Saag KG, Singer AJ, Siris ES (2022) The clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int 33:2049\u20132102. https:\/\/doi.org\/10.1007\/s00198-021-05900-y","journal-title":"Osteoporos Int"},{"key":"1735_CR2","doi-asserted-by":"publisher","first-page":"2137","DOI":"10.1007\/s00198-022-06454-3","volume":"33","author":"PL Xiao","year":"2022","unstructured":"Xiao PL, Cui AY, Hsu CJ, Peng R, Jiang N, Xu XH, Ma YG, Liu D, Lu HD (2022) Global, regional prevalence, and risk factors of osteoporosis according to the World Health Organization diagnostic criteria: a systematic review and meta-analysis. Osteoporos Int 33:2137\u20132153. https:\/\/doi.org\/10.1007\/s00198-022-06454-3","journal-title":"Osteoporos Int"},{"key":"1735_CR3","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1186\/s13018-021-02772-0","volume":"16","author":"N Salari","year":"2021","unstructured":"Salari N, Ghasemi H, Mohammadi L, Behzadi MH, Rabieenia E, Shohaimi S, Mohammadi M (2021) The global prevalence of osteoporosis in the world: a comprehensive systematic review and meta-analysis. J Orthop Surg Res 16:609. https:\/\/doi.org\/10.1186\/s13018-021-02772-0","journal-title":"J Orthop Surg Res"},{"key":"1735_CR4","first-page":"882","volume":"22","author":"H Wu","year":"2022","unstructured":"Wu H, Liu Y, Lan Y, Zhong J (2022) Prevalence of osteoporosis in Chinese postmenopausal females: a meta-analysis. Zhongguo Xun Zheng Yi Xue Za Zhi 22:882\u2013890","journal-title":"Zhongguo Xun Zheng Yi Xue Za Zhi"},{"key":"1735_CR5","doi-asserted-by":"publisher","first-page":"466","DOI":"10.1080\/13697137.2024.2380363","volume":"27","author":"VJ Wright","year":"2024","unstructured":"Wright VJ, Schwartzman JD, Itinoche R, Wittstein J (2024) The musculoskeletal syndrome of menopause. Climacteric 27:466\u2013472. https:\/\/doi.org\/10.1080\/13697137.2024.2380363","journal-title":"Climacteric"},{"key":"1735_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1007\/s43465-023-01058-3","volume":"57","author":"SS Amarnath","year":"2023","unstructured":"Amarnath SS, Kumar V, Das SL (2023) Classification of osteoporosis. Indian J Orthop 57:49\u201354. https:\/\/doi.org\/10.1007\/s43465-023-01058-3","journal-title":"Indian J Orthop"},{"key":"1735_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031376","volume":"23","author":"CH Cheng","year":"2022","unstructured":"Cheng CH, Chen LR, Chen KH (2022) Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover. Int J Mol Sci 23:1376. https:\/\/doi.org\/10.3390\/ijms23031376","journal-title":"Int J Mol Sci"},{"key":"1735_CR8","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1016\/j.bone.2011.07.011","volume":"49","author":"T Matsumoto","year":"2011","unstructured":"Matsumoto T, Ito M, Hayashi Y, Hirota T, Tanigawara Y, Sone T, Fukunaga M, Shiraki M, Nakamura T (2011) A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures--a randomized, active comparator, double-blind study. Bone 49:605\u2013612. https:\/\/doi.org\/10.1016\/j.bone.2011.07.011","journal-title":"Bone"},{"key":"1735_CR9","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1007\/s00774-019-01009-9","volume":"37","author":"Y Jiang","year":"2019","unstructured":"Jiang Y, Tang H, Ma X, Cheng Q, Lin H, Jin X, Zhang Z, Yu W, He S, Kobayashi T, Uehara S, Matsumoto T, Xia W (2019) Eldecalcitol increases bone mineral density in Chinese osteoporotic patients without vitamin D or calcium supplementation. J Bone Miner Metab 37:1036\u20131047. https:\/\/doi.org\/10.1007\/s00774-019-01009-9","journal-title":"J Bone Miner Metab"},{"key":"1735_CR10","first-page":"299","volume":"39","author":"K Miyata","year":"2011","unstructured":"Miyata K, Abe M, Terao K, Kawanishi T, Tsuji N, Shiraki M, Nakamura T, Matsumoto T, Tanigawara Y (2011) Pharmacokinetics of eldecalcitol in primary osteoporosis patients\u2014randomized, double-blind, multicentre, long-term phase III clinical study. Jpn Pharmacol Ther 39:299\u2013307","journal-title":"Jpn Pharmacol Ther"},{"key":"1735_CR11","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1007\/s00774-016-0779-2","volume":"35","author":"H Saito","year":"2017","unstructured":"Saito H, Kakihata H, Nishida Y, Yatomi S, Nihojima S, Kobayashi Y, Tabata H, Nomura M (2017) The safety and effectiveness profile of eldecalcitol in a prospective, post-marketing observational study in Japanese patients with osteoporosis: interim report. J Bone Miner Metab 35:456\u2013463. https:\/\/doi.org\/10.1007\/s00774-016-0779-2","journal-title":"J Bone Miner Metab"},{"key":"1735_CR12","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1007\/s00774-021-01276-5","volume":"40","author":"Y Takeuchi","year":"2022","unstructured":"Takeuchi Y, Saito H, Makishima M, Yokoyama H, Yamaguchi T, Fujii H, Inoue E, Isemura T, Kondo S (2022) Long-term safety of eldecalcitol in Japanese patients with osteoporosis: a retrospective, large-scale database study. J Bone Miner Metab 40:275\u2013291. https:\/\/doi.org\/10.1007\/s00774-021-01276-5","journal-title":"J Bone Miner Metab"},{"key":"1735_CR13","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.3945\/ajcn.116.134981","volume":"104","author":"Z Malihi","year":"2016","unstructured":"Malihi Z, Wu Z, Stewart AW, Lawes CM, Scragg R (2016) Hypercalcemia, hypercalciuria, and kidney stones in long-term studies of vitamin D supplementation: a systematic review and meta-analysis. Am J Clin Nutr 104:1039\u20131051. https:\/\/doi.org\/10.3945\/ajcn.116.134981","journal-title":"Am J Clin Nutr"},{"key":"1735_CR14","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1253\/circj.CJ-17-0177","volume":"81","author":"N Takashima","year":"2017","unstructured":"Takashima N, Arima H, Kita Y, Fujii T, Miyamatsu N, Komori M, Sugimoto Y, Nagata S, Miura K, Nozaki K (2017) Incidence, management and short-term outcome of stroke in a general population of 1.4 million Japanese\u2013Shiga Stroke Registry. Circ J 81:1636\u20131646. https:\/\/doi.org\/10.1253\/circj.CJ-17-0177","journal-title":"Circ J"},{"key":"1735_CR15","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1159\/000543474","volume":"59","author":"H Sun","year":"2025","unstructured":"Sun H, Ge S, Jiang B, Ru X, Sun D, Wang L, Zhang M, Wang W (2025) Incidence of first-ever stroke, stroke events, and early case fatality rate in China: results from a national population-based survey. Neuroepidemiology. https:\/\/doi.org\/10.1159\/000543474","journal-title":"Neuroepidemiology"}],"container-title":["Journal of Bone and Mineral Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01735-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01735-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00774-026-01735-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T18:43:59Z","timestamp":1793472239000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00774-026-01735-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":15,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1735"],"URL":"https:\/\/doi.org\/10.1007\/s00774-026-01735-x","relation":{},"ISSN":["0914-8779","1435-5604"],"issn-type":[{"value":"0914-8779","type":"print"},{"value":"1435-5604","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,16]]},"assertion":[{"value":"23 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Shun Chiba, Chiemi Yamagiwa and Tomohiro Yamaguchi are employees of Chugai Pharmaceutical Co., Ltd. Zheng Ke is an employee of Chugai Pharma China Co., Ltd. Weibo Xia received consulting fees from Chugai Pharmaceutical Co., Ltd. and payments for lectures and presentations from Chugai Pharmaceutical Co., Ltd. Yasuhiro Takeuchi received consulting fees from Chugai Pharmaceutical Co., Ltd. and payments for lectures and presentations from Chugai Pharmaceutical Co., Ltd., Teijin Pharma Ltd., Daiichi-Sankyo Inc., Amgen Inc., Astellas Pharma Inc., and Asahi Kasei Pharma Corp.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol and associated documents were approved by Independent Ethics Committees at each study site before starting the study. Written informed consent was provided by the patient or the patient\u2019s legally acceptable representative before study participation.","order":2,"name":"Ethics","label":"Ethical approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}